Skip to main content

Table 2 Comparison of characteristics among PMBL and three subgroups of DLBCL

From: DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation

Ā 

DLBCL

PMBCL

p_value (Ļ‡2 test)

Others

MYD88_L265P

JAK2/PD-L2_amp

Patients

53 (65.43%)

15 (18.52%)

8 (9.88%)

5 (6.17%)

Ā 

Age

0.003*

ā€ƒmedian (range)

57 (23ā€“80)

57 (31ā€“88)

47 (27ā€“70)

27 (19ā€“36)

Ā 

BM

0.520

ā€ƒNegative

46 (86.79%)

14 (93.33%)

8 (100.00%)

5 (100.00%)

Ā 

ā€ƒPositive

7 (13.21%)

1 (6.67%)

0 (00.00%)

0 (00.00%)

Ā 

IHC Hansā€™ algorithm

0.806

ā€ƒGCB

16 (30.19%)

3 (20.00%)

2 (25.00%)

2 (40.00%)

Ā 

ā€ƒNon-GCB

37 (69.81%)

12 (80.00%)

6 (75.00%)

3 (60.00%)

Ā 

IPI

0.522

ā€ƒLow-risk

26 (49.06%)

7 (46.67%)

2 (25.00%)

4 (80.00%)

Ā 

ā€ƒLow_intermediate

12 (22.64%)

5 (33.33%)

3 (37.50%)

0 (00.00%)

Ā 

ā€ƒHigh_intermediate

7 (13.21%)

3 (20.00%)

2 (25.00%)

1 (20.00%)

Ā 

ā€ƒHigh

8 (15.09%)

0 (00.00%)

1 (12.50%)

0 (00.00%)

Ā 

MYC Breakapart

0.822

ā€ƒNegative

50 (94.34%)

14 (93.33%)

7 (87.50%)

5 (100.00%)

Ā 

ā€ƒPositive

3 (05.66%)

1 (06.67%)

1 (12.50%)

0 (00.00%)

Ā 
  1. * Kruskal-Wallis rank sum test